CLINICAL TRIALS PROFILE FOR TECHNETIUM TC-99M SODIUM PERTECHNETATE
✉ Email this page to a colleague
All Clinical Trials for technetium tc-99m sodium pertechnetate
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT03120624 ↗ | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Recruiting | National Cancer Institute (NCI) | Phase 1 | 2017-09-15 | This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone. |
| NCT03120624 ↗ | VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Patients With Stage IV or Recurrent Endometrial Cancer | Recruiting | Mayo Clinic | Phase 1 | 2017-09-15 | This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV endometrial cancer or endometrial cancer that has come back. The study virus, VSV-hIFNbeta-NIS, has been changed so that it has restricted ability to spread to tumor cells and not to healthy cells. It also contains a gene for a protein, NIS, which helps the body concentrate iodine making it possible to track where the virus goes. VSV-hIFNbeta-NIS may be able to kill tumor cells without damaging normal cells. Ruxolitinib phosphate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving VSV-hIFNbeta-NIS with ruxolitinib phosphate may work better in treating patients with endometrial cancer compared to VSV-hIFNbeta-NIS alone. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for technetium tc-99m sodium pertechnetate
Condition Name
| Condition Name for technetium tc-99m sodium pertechnetate | |
| Intervention | Trials |
| Recurrent Endometrial Adenocarcinoma | 1 |
| Stage IVA Uterine Corpus Cancer | 1 |
| Recurrent Endometrial Carcinoma | 1 |
| Stage IVA Uterine Corpus Cancer AJCC v7 | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for technetium tc-99m sodium pertechnetate
Trials by Country
Clinical Trial Progress for technetium tc-99m sodium pertechnetate
Clinical Trial Phase
Clinical Trial Sponsors for technetium tc-99m sodium pertechnetate
Sponsor Name
